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The polycomb repressive complex 2 (PRC2) maintains the transcriptional repression of
target genes through its catalytic component enhancer of zeste homolog 2 (EZH2).
Through modulating critical gene expression, EZH2 also plays a role in cancer
development and progression by promoting cancer cell survival and invasion. Mutations
in EZH2 are prevalent in certain B-cell lymphoma subtypes such as diffuse large cell
lymphoma and follicular lymphoma; while no EZH2 mutation has been reported in the
mantle cell lymphoma (MCL). Here we demonstrate that the PRC2 components EZH2,
EED and SUZ12 are upregulated in the MCL cells as compared to normal B-cells.
Moreover, stably transfected cells with wild-type EZH2 or-EED showed increased cell
growth and H3K27-trimehtylation. However, unlike wild-type EZH2, ectopic expression
of a deletion construct of EZH2 (EZH21550−738 lacking SET domain) had no growth
advantage over control cells. Pharmacological inhibition of EZH2 suppressed H3K27me3
and had significant inhibitory effect on cell growth and colony forming capacity (p < 0.05)
of MCL cells, and this effect was more or less comparable to the anti-proliferative effects
of EZH2 inhibition in cells harboring EZH2-mutation. Mechanistically, EZH2 appears
to downregulate expression of cdkn2b gene via enhanced H3K27me3, a well-known
suppressive epigenetic mark, at the cdkn2b promoter region. Overall, these results
highlight that deregulation of PRC2/EZH2 is associated with epigenetic suppression of
cdkn2b in MCL, and in part responsible for increased cell growth, thus the EZH2 inhibitors
may have therapeutic potential in the patients with MCL.
Keywords: MCL, PRC2, EZH2, H3K27me3, cdkn2b

INTRODUCTION
Mantle cell lymphoma (MCL) is an aggressive form of B cell lymphoma, which accounts for ∼6%
of all non-Hodgkin lymphomas (NHL) (1, 2). Treatment outcome in MCL appears to be improving
with help of novel targeted agents including ibrutinib (3, 4). Nevertheless, patients do relapse,
often with emergence of drug resistance, which remains a critical barrier to the current treatment

1

July 2020 | Volume 10 | Article 1226

Demosthenous et al.

Role of PRC2 in Mantle Cell Lymphoma

from the Cell Signaling Technologies (Beverly, MA, USA).
Antoibodies to H3K27me1 (cat#ab175037), H3K27me2
(cat#ab24684) and EED (cat#ab231812) were from Abcam
(Cambridge, MA, USA), while the anti-β-Actin (cat#sc47778)
antibody was procured from Santa Cruz Biotechnology (Dallas,
TX, USA). EZH2 specific inhibitors GSK343, GSK126 and
methyltransferase inhibitor DZNep were purchased from the
Sigma-Aldrich (St Louis, MO, USA).

strategies. Therefore, identifying alternative approaches to
overcome drug resistance in the relapsed MCL is an urgent
unmet medical need. Polycomb repressive complex 2 (PRC2),
is an important epigenetic regulator that comprises three main
components: enhancer of zeste homolog 2 (EZH2), zinc fingercontaining SUZ12 and WD40-repeat protein EED. EZH2 is the
catalytic component of the PRC2 and represents a key a histone
methyltransferase primarily involved in transfer of methyl groups
to the lysine 27 residue of histone H3 (H3K27) through its
C-terminal SET domain (5). Importantly, EZH2 gains histone
methyltransferase activity only when it complexes with other 2
subunits, EED and SUZ12 to form PRC2 (6–9).
Overexpression of EZH2 in tumor cells has been implicated
in tumor growth, and has inverse correlation with treatment
outcome in various cancer types (10–14). In B cell lymphoma,
aberrancy of EZH2 has been associated with EZH2 tyrosine
641 (Y641N) mutation seen in ∼22% of diffuse large Bcell lymphoma (DLBCL) and 7% of follicular lymphoma (FL)
patients (15–17). However, EZH2 mutations have not been
reported in the MCL patient samples or human MCL cell
lines (18, 19). Apart from pathogenic mutations, genetic lesions
of EZH2, including copy number amplification, chromosomal
gain or loss have been reported in DLBCL and FL (20, 21).
Besides genetic alterations, the epigenetic regulation of EZH2
expression and its activity via promoter methylation, microRNA
and lncRNA have also been reported (22). Notably, we have
previously shown that lncRNA ROR1-AS1 expressed in MCL,
can modulate activity of EZH2 (23). Given the importance of
EZH2 dysregulation in cancers including lymphoma, there is
growing interest in EZH2 inhibitors and a number of EZH2
inhibitors are under various stages of clinical development (24).
Although several studies have previously shown oncogenic role
of mutant-EZH2 found in DLBCL and FL (15, 16, 25), studies
aimed at understanding the role of wild type (wt) EZH2 in other
lymphoma subtypes such as MCL, are lacking. The present study
was designed to comprehensively evaluate role of PRC2 in MCL
and to study the implications of targeting H3K27 methylation
events through pharmacological inhibitors of EZH2.

Plasmid Construction and Stable
Transfection
Full length cDNA encoding EZH2WT was PCR amplified using
custom made forward and reverse primers. The PCR fragments
were cloned into an intermediate vector pCR2.1-TOPO-TA
(Thermo-Fisher), sequence verified and subsequently cloned into
pLEX-MCS lentiviral vector. The viral particles were packaged
using Viral System Protocols (Dharmacon) and HEK293 cells
were virally transduced and selected with 500 ng/ml puromycin
as previously described (26).

Transient Cell Transfection
HEK293-T cells were transfected with 5.0 µg of plasmids
(PCDNA3.1 empty vector or carrying EZH2WT or
EZH21550−738 ) using lipofectamine-2000 (Invitrogen, Grand
Island, NY, USA) for 24 h as previously described (26).

Co-immunoprecipitation (Co-IP) and
Western Blotting
For the co-immunoprecipitation assay, 5 µg of EZH2 antibody
was added to the lysates and incubated with continuous shaking
at 4◦ C, the immune-precipitates were then pulled down using
protein G-Agarose beads, washed four times with the lysis buffer
and denatured. The protein acrylamide gel electrophoresis and
western blotting was performed as previously described (27).
Briefly, the proteins resolved by SDS-PAGE were transferred to
PVDF membrane. The membranes were incubated in blocking
solution 5% non-fat milk dissolved in PBS, 0.1% Tween-20
(PBST), and subsequently with the indicated primary antibodies
at 4◦ C overnight. The membranes were then washed in PBST
and incubated with HRP-conjugated secondary antibodies for
1 h at room temperature and the signal developed by enhanced
chemiluminescent reagent and captured by the autoradiography.
Densitometry on original western blots was quantified by
ImageJ software and the signal was normalized to corresponding
control lane.

MATERIALS AND METHODS
Cell Lines
Human MCL lines Jeko, Mino, Granta, JVM2, and Z138
purchased from ATCC (Manassas, VA) were grown in RPMI
supplemented with 10% Fetal Bovine Serum (FBS) and 1%
streptomycin/penicillin. HEK293T cell line was obtained from
Open Biosystems (Huntsville, AL, USA) and was cultured
in the DMEM supplemented with 10% Fetal Bovine Serum
(FBS). Cell lines were authenticated by STR Profiling performed
at the ATCC and Genetica (Burlington, NC USA). CD19+
B-cells were sorted form the peripheral blood mononuclear
cells isolated from healthy donors using EasySep isolation kit
(STEMCELL Technologies).

Quantitative Reverse Transcription-PCR
(Q-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA) and Q-PCR was performed as previously
described (28). Relative mRNA expression was calculated using
the 11Ct method (29) after normalization, the primers used
were as follows (all sequences from 5 to 3′ ):
β-actin -forward primer: GCCGCCAGCTCACCAT
β-actin -reverse primer: TCGATGGGGTACTTCAGGGT
cdkn2b -forward primer: GGACTAGTGGAGAAGGTGCG
cdkn2b -reverse primer: GGGC GCTGCCCATCATCATG

Antibodies and Drugs
Antibodies against EZH2 (cat#4905), SUZ12 (cat#3737), histone
H3 (cat#4499) and H3K27me3 (cat#9733) were purchased
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levels of EZH2, H3K27me3, SUZ12, and EED than the FL cell
line DOHH2 carrying EZH2WT , and had PRC2 components
comparable to that of MCL cell lines (Figure 1A). Interestingly,
the expression of PRC2 components EZH2, EED, and SUZ12
was lower in CD19+ normal B-cells as compared to that in
lymphoma cell lines. Moreover, the global level of H3K27trimethylation in the lymphoma cell lines was more or less similar
to that of normal B cells (Supplementary Figure S1). These
results indicate that the levels of EZH2, SUZ12, and EED (PRC2
components) are upregulated in lymphoma cells as compared
to normal B cells, but this is not the case for global levels of
H3K27 tri-methylation.
Confirming the interaction among various components of
PRC2, SUZ12, and EED co-immuno-precipitated in an EZH2
pulled down assay using anti-EZH2 antibody, and the pull-down
efficiency of PRC2 components with anti-EZH2 antibody was
comparable in the MCL and FL cell lines (Figures 1B,C). Overall,
these results demonstrate that dysregulation of PRC2 in MCL
cells is essentially similar to that in Karpas-422, a FL cell line
carrying Y641N mutation in EZH2.

cdkn2a -forward primer: GAAGGTCCCTCAGACATCCCC
cdkn2a -reverse primer: CCCTGTAGGACCTTCGGTGAC

Chromatin Immunoprecipitation (ChIP)
Assay
ChIP assays were carried out using Simple ChIP R Enzymatic
Chromatin IP Kit (9003, Cell Signaling Technology) using antiH3K27me3 antibody and control IgG as per instruction manual.
Briefly, the nuclei isolated from Mino or JVM2 cell lines cultured
in absence or presence of 5 µM GSK126, were processed as
per instruction manual. The immuno-precipitated DNA and
the input samples were analyzed by quantitative PCR using the
following primers:
cdkn2b -forward primer: 5′ - CCTTCCCTGTCCAGGTGGAT
TT-3′ ,
cdkn2b -reverse primer: 5′ -ACCTTAGCTCTGACTCCTCAT
CC-3 ′ .

Proliferation and Survival Assays
For thymidine incorporation assay, MCL cells were cultured for
48 h at 37◦ C in 96-well plates and the thymidine incorporation or
MTT assays were performed as previously described (27, 30). For
assessment of cell survival, 5 × 105 cells per well were cultured
in the absence or presence of various drug doses for 48 h and
subsequently analyzed by flow cytometry using Annexin V and
propidium iodide as previously described (27).

Effect of Ectopic Expression of EZH2 or
EED on Cell Growth and Histone
Methylation
EZH2 is the enzymatic subunit of PRC2 complex (5), whereas
EED, is an essential component required for allosteric activation
of methyltransferase activity (35). To elucidate effects of
EZH2 and EED overexpression on methyltransferase activity
and cell growth, full length EZH2 and EED cDNA were
expressed in the HEK-293T cells. Since we were unable to
achieve stable overexpression of EZH2 or EED in the MCL
cell lines using lentiviral system despite multiple attempts,
EZH2 or EED expression vectors were transduced in HEK293 cells (Figure 2A). Overexpression of full length EZH2
or EED (EZH2WT or EEDWT ) led to a markedly increased
H3K27me3 and to a lesser extent the di-methylation of
H3K27 (H3K27me2) marks as compared to corresponding
empty vector controls. However, increased level of H3K27me1
was only observed with overexpression of EED but not with
EZH2 overexpression (Figure 2B). These results indicate that
overexpression of EZH2 or EED is associated with dysregulation
of histone methyltransferase activity of PRC2. Next, we assessed
the effect of the EZH2 or EED overexpression on cell growth.
Results from an MTT assay showed that overexpression of EED
or EZH2 significantly (p = 0.05) promotes cell proliferation
as compared an empty vector (Figure 2C). Overall, these
results suggest that dysregulation of methyltransferase activity
of PRC2 by overexpression of EZH2 or EED can promote
cell growth.

Colony-Forming Unit (CFU) Assay
For CFU assay, 2 × 103 cells suspended in 50 µl culture
medium were added to 0.5 ml MethocultTM H4230 (STEMCELL,
Vancouver, Canada) with or without EZH2 inhibitor per well in
24-well plates and incubated at 37◦ C for 10 days.

Statistics
The data presented is the mean ± standard error from 3
independent experiments. An unpaired Student’s T-test was used
for statistical comparisons and p < 0.05 considered significant.

RESULTS
Upregulation of PRC2 Components in MCL
Cells
PRC2 is an epigenetic suppressive complex and plays an
important role in modulating gene transcription throughout
the stages of development and in various diseases including
lymphoma (16, 31–33). To understand potential role of PRC2
in MCL, we first analyzed expression of PRC2 components
in MCL cell lines and comparing with FL cell lines, Karpas
422 and DOHH2 differing by EZH2-mutation status. The MCL
cell lines used here have been previously described to express
a wild-type EZH2 (EZH2WT ), while FL cell lines, Karpas 422
and DOHH2 are known to express EZH2mutant and EZH2WT ,
respectively (18, 34). Consistent with dysregulation of PRC2 in
several human cancers, a robust expression of EZH2, SUZ12,
and EED proteins was seen on the western blots for all MCL
cell lines analyzed (Figure 1A). However, FL cell line Karpas
422, carrying EZH2Y641N mutation exhibited slightly higher

Frontiers in Oncology | www.frontiersin.org

Pro-growth Function of PRC2 Depends on
the EZH2 SET Domain
EZH2 is the catalytic subunit of the PRC2, and its C-terminal
SET domain exhibits methyltransferase activity. To elucidate the
biological significance of EZH2 SET-domain in cell proliferation
we cloned full-length EZH2 (EZH2WT ) or a SET-domain
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FIGURE 1 | Expression of the PRC2 components in MCL and FL cells. (A) Western blot images showing expression of PRC2 components EZH2, SUZ12, and EED in
lysates of MCL and FL cell lines, β-Actin was used as a loading control; levels of H3K27-trimethylation (H3K27me3) were detected to assess PRC2 activity, where
Histone H3 served as a loading control. (B,C) immunoblots showing enrichment of SUZ12 and EED in proteins immuno-precipitated with anti-EZH2 antibody or control
IgG from lysates of MCL cell lines, Mino and Granta, carrying WT EZH2 (B), or FL cell lines, DOHH2 and Karpas-422, carrying WT and mutant EZH2, respectively (C).

Frontiers in Oncology | www.frontiersin.org
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FIGURE 2 | Effect of EZH2 or EED transfection on H3K27-methylation and cell growth. (A) Western blot analysis shows overexpression of EZH2 and EED in stably
transfected HEK293T cells, β-Actin was used as a loading control. (B) western blot images showing levels of H3K27me1, H3K27me2, and H3K27me3 in HEK293T
cells transfected with an empty vector (pLEX) or the vector containing full length EZH2 or EED, histone H3 was used as loading control. (C) Bar graphs showing
relative cell proliferation as determined by MTT assay in the HEK293T cells transfected with empty vector (pLEX) or vector containing EZH2 or EED, bars represent
mean ± SD from 3 different experiments (*p < 0.05).

Growth Inhibitory Effects of
Pharmacological Inhibition of EZH2 in MCL
Cells

deletion construct (EZH21550−738 ) into pCDNA3.1 mammalian
expression vector and transiently transfected into the HEK293
cells (Figures 3A,B). We then sought to determine the effect
of ectopically expressed EZH2WT and EZH21550−738 constructs
on cell growth by MTT assay. Unlike, full-length EZH2, which
led to significant increase in cell growth, overexpression of
EZH21550−738 , had no significant growth advantage over cells
transfected with an empty vector (Figure 3C). Overall these
results suggest that EZH2, overexpression has the potential to
increase cell growth.

Frontiers in Oncology | www.frontiersin.org

There is growing interest in clinical development of EZH2
inhibitors in lymphoma, and selective EZH2 inhibitor have
shown promising activity in EZH2 mutant cells (34, 36).
The effect of EZH2 inhibition on suppressive histone marks
H3K27me2/3 was assessed in Granta cells. Western blot analysis
of H3K27me2/3 showed marked reduction in H3K27me3 and
H3K27me2 marks after GSK343 treatment; however, the effect
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FIGURE 3 | Effect of ectopic expression of truncated EZH2 or EED on histone methylation and cell growth. (A) Schematic depiction of full-length and truncated EZH2
constructs. (B) Representative western blot images showing overexpression of full length (EZH2WT ) or truncated EZH2 (EZH21550−738 ). (C) graphs showing relative
cell proliferation (as determined by the MTT assay) in the HEK293T cells transfected with an empty vector (pcDNA3.1) or pcDNA3.1 carrying full length EZH2
(EZH2WT ) or truncated EZH2 (EZH21550−738 ). Bars represent mean ± SD from 3 different experiments (**p < 0.01).

among FL cell lines, DOHH2EZH2WT vs. Karpas 422EZH2/Y641N
(Figure 4D) indicating an inherent hypersensitivity to EZH2
inhibitors in FL cells that is unrelated to EZH2 mutation. In a
cell survival assay, 10 µM GSK343 had no significant effect, while
20 µM GSK343 decreased survival by ∼45–50% in Mino and
Granta cell lines, but no significant inhibitory effect was observed
in Z138 cell line (Figure 4E). Consistent with a more pronounced
anti-proliferative effects EZH2 inhibition in FL cells, treatment
with GSK343 also had more pronounced effect on cell survival
in FL cell lines, where 20 µM GSK343 reduced survival to only
20 and 40% in DOHH2 and Karpas422 cell lines, respectively
(Figure 4F). To further confirm growth inhibitory effect of
EZH2 blockade in MCL cells, we performed colony-forming
unit (CFU) assay. Consistent with results from proliferation and
survival assays, CFU assay showed significant reduction in colony
formation in the presence of GSK126 as compared to untreated
controls (Supplementary Figures S2A,B). Overall, these results
suggest that PRC2 dysregulation regardless of pathogenic EZH2
mutations, can enhance growth potential in MCL and FL cell
lines with or without EZH2 mutations. These results suggest that
deregulation of PRC2 and its oncogenic potential is much more
prevalent in lymphoma subtypes than previously realized.

of GSK343 was relatively more pronounced on H3K27me3 than
H3K27me2 epigenetic marks (Figure 4A). Similarly, DZNep, a
global methyltransferase inhibitor decreased H3K27me3 but had
no appreciable effect on H3K27me2 histone marks. Furthermore,
EZH2 inhibition by the GSK343 or DZNep decreased PRC2
formation by prohibiting interaction between EZH2 and EED
as determined by co-immunoprecipitation assay (Figure 4B).
Overall these results suggest that PRC2 can be targeted
in MCL with GSK343, which is relatively more effective
than DZNep.
We then sought to analyze effects of EZH2 specific inhibitors
GSK343 or GSK126, on proliferation and survival of MCL (Mino,
Granta and Z138) and FL cell lines (DOHH2 carrying EZH2WT
and Karpas 422 carrying mutant EZH2Y641N ). Treatment with
10 µM GSK343 reduced proliferation of Mino and Granta cells
by 25 and 40%, respectively, while 20 µM GSK343 completely
obliterated growth of these cell lines (Figure 4C). Similar
anti-proliferative effects of GSK126, a different EZH2 inhibitor,
were seen with Mino and JVM2 cell lines (data not shown).
Interestingly, although GSK343 rendered more prominent antiproliferative effects in FL cells than in MCL cells, there was
no significant difference in anti-proliferative activity of GSK343

Frontiers in Oncology | www.frontiersin.org
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FIGURE 4 | Effects of pharmacological inhibition of EZH2 on growth and PRC2 integrity in lymphoma cells. (A) Representative western blot images showing
H3K27me2 and H3K27me3 in Granta cells treated with GSK343 or DZNep used at indicated concentrations for 48 h, β-Actin and the histone H3 were used as
(Continued)
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FIGURE 4 | loading controls. The numbers underlining each western blot image represent relative band intensity as compared to the control lane in same blot. (B)
Representative images showing levels of EED or EZH2 in proteins immuno-precipitates using either IgG or anti-EZH2 antibody along with 5% input from the lysates of
Granta cells treated with EZH2 inhibitors as indicated. (C–F) MCL cell lines (left panel) and FL cells (right panel) were treated with various concentrations of EZH2
inhibitor GSK343 for 72 h. Proliferation (C,D) and survival (E,F) was assessed by thymidine incorporation and Annexin V/PI exclusion, respectively. Bars represent
mean ± SD from 3 different experiments (*P < 0.05).

Epigenetic Effect of EZH2 Inhibition on Cell
Cycle Regulatory Genes in MCL

findings are consistent with the previous study by others
(39, 40). To take the concept of PRC2 overexpression
one step further, immunoprecipitation studies showed that
histone methyltransferase complex is enzymatically active in
proliferating MCL cells in absence of known EZH2 mutations.
Collectively, these data show that PRC2 is aberrantly active
in MCL cells. Consistent with prior studies suggesting protumorigenic role of PRC2 (34, 35), overexpression of wt-EZH2
was associated with enhanced proliferation. Patients with MCL
requiring treatment, receive either combination of intensive
chemotherapy backbone incorporating high dose cytarabine and
rituximab or a combination of bendamustine and rituximab
(41). Despite this standard of care treatment, patients do relapse
and often with emergence of drug resistance. EZH2 is an
attractive drug target in cancer, which has inspired clinical
development of EZH2 inhibitors to target mutant EZH2 (42, 43).
Our results suggest that EZH2 inhibitors can inhibit H3K27 trimethylation by disrupting interaction between EZH2 and EED
in MCL cell harboring wt-EZH2. Importantly, treatment with
EZH2 inhibitors led to significant growth inhibition and cell
killing, which was comparable to the activity of EZH2 inhibitors
in lymphoma cells harboring gain-of-function mutations in
EZH2. Considering the deregulation of PRC2 is associated
with growth potential of lymphoma cells, targeting PRC2
with EZH2 inhibitors is a reasonable therapeutic approach
to aggressive lymphomas. However, considering important
role of PRC2 in B-cell development, use of EZH2 inhibitors
will need caution to prevent potential adverse effects on
hematopoietic homeostasis. Nevertheless, our results are in
accordance with a prior study performed by Zhang et al.
(44) who demonstrated reduced survival of MCL cells using
DZNep (44).
Studies in MCL patient samples have shown DNA hypermethylation of key genes implicated in cell cycle regulation,
such as cdkn2a and cdkn2b (37, 38, 45). Our study showed
that EZH2 inhibition can restore cdkn2b expression by
altering epigenetic landscape of histone methylation marks,
and support the notion that cdkn2b is a direct target of
PRC2/EZH2 in MCL. Our results are in line with prior
study where cdkn2b repression was associated with epigenetic
alterations in the form of DNA methylation as well as EZH2
mediated suppressive histone marks that were reversed by
the epigenetic drugs (46). Consistent with the later scenario,
the abundance of H3K27me3 suppressive histone marks were
detected in promoter region of cdkn2b in MCL cells, which
was reduced by the EZH2 inhibition. Whether EZH2 can
act independently or requires DNA hyper-methylation to
silence cdkn2b in MCL is not clear. Nevertheless, the data
reported here indicate that overexpression of EZH2 (with
or without activating mutations) may confer a similar

To understand how EZH2 confers growth advantage in the MCL
cell lines, we focused on our attention to the cell cycle regulators,
which are most commonly disrupted or deregulated either by
homozygous deletion or epigenetic silencing via promoter hypermethylation of cdkn2b (p15), and/or cdkn2a (p16) loci (37,
38). To understand potential role of EZH2 in regulation of
cdkn2a and/or cdkn2b, we first determined the impact of EZH2
inhibition on expression of cdkn2a and cdkn2b in Mino and
JVM2 cells. Interestingly, EZH2 inhibition have modest (2–4folds) but statistically significant upregulation of cdkn2a, while
the effect on expression of the cdkn2b was highly remarkably
upregulated e (∼20–30-folds, p = 0.005 as compared to control)
(Figures 5A,B). These analyses indicate that EZH2 (PRC2) can
promote growth of lymphoma cells via suppression of cdkn2b
and/or cdkn2a.
To understand the mechanism of EZH2 mediated regulation
of cdkn2b, we performed chromatin immunoprecipitation
(ChIP) assays on MCL cells cultured in absence or presence of
GSK126 using the anti-H3K27me3 antibody or IgG control, and
the primers against cdkn2b promoter as depicted in Figure 5C.
Results from ChIP assay showed that the inhibition of EZH2 by
GSK126 significantly (p = 0.005) decreased H3K27me3 marks
in the promoter region of cdkn2b both in Mino and JVM2 cell
lines (Figures 5D,E). Overall, these results suggest that EZH2
promotes H3K27me3 repressive histone marks on promoter
region of cdkn2b, which in turn can repress cdkn2b gene.

DISCUSSION
PRC2 is an epigenetic suppressive complex, which plays an
important role in gene transcription in various diseases (16, 31–
33). Histone methyltransferase EZH2 is the catalytic subunit
of PRC2, and the tyrosine 641 (Y641) of EZH2 is the most
frequently mutated residue, up to 22% of germinal center-derived
lymphomas and 24% of FL acquiring mutations at this site
(16, 17). These mutations appear to modify enzymatic activity of
EZH2 (32, 33). However, such EZH2 activating mutations, have
not been reported or identified in the whole exome sequencing
data from MCL patient samples (18, 19), as a result, the role
of PRC2 and wt-EZH2 in MCL has been historically considered
to be limited. However, our results from this study suggest that
PRC2 may have tremendous therapeutic implication considering
MCL is an aggressive B-cell lymphoma with frequent relapses.
In the current study, we have demonstrated that PRC2
components, EZH2, SUZ12, and EED, are highly overexpressed
in MCL cell lines as compared to the normal B-cells
isolated from the peripheral blood of healthy donors. These

Frontiers in Oncology | www.frontiersin.org
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FIGURE 5 | Effect of EZH2 inhibition on expression of tumor suppressor genes in MCL cell lines. (A,B) Bar graphs showing relative mRNA transcript of cdkn2a and
cdkn2b as determined by QRT-PCR in Mino (A) or JVM2 (B) MCL cell lines treated with EZH2 inhibitor for 48 h. (C). Schematic diagram of promoter region of cdkn2b
used in ChIP assays, sequence of primers and location of targeted region has been depicted. (D,E) Bar graphs showing fold enrichment of promoter region of cdkn2b
gene after ChIP with anti-H3K27me3 antibody as compared to input in Mino (D) or JVM2 (E) cells cultured in absence or presence of GSK126. Bars represent mean
± SD from 3 different experiments, *p < 0.05, and **p < 0.01 for the comparison of cdkn2b amplicon in ChIP with H3K27me3 antibody in control versus GSK126
treated cells.
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